FDA DEVICE FACTS
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Ventana Medical Systems, Inc.
Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。
Indications for use
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (PATHWAY anti-HER2 (4B5) antibody) is a rabbit monoclonal antibody intended for laboratory use for the semi-quantitative detection of HER2 antigen by immunohistochemistry (IHC) in sections of formalin-fixed, paraffin-embedded breast carcinoma, biliary tract cancer (gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) and gastroesophageal adenocarcinoma (gastric, gastroesophageal
Page 2 junction and esophageal adenocarcinoma) tissue using the ultraView Universal DAB Detection Kit on a BenchMark ULTRA or BenchMark ULTRA PLUS instrument.
The IHC device is indicated for identifying patients who are eligible for treatment with the following therapies in accordance with the approved therapeutic labeling:
Indication for use HER2 Score Therapy Breast carcinoma IHC 3+ or IHC 2+/ISH amplified Herceptin® Breast carcinoma IHC 3+ or IHC 2+/ISH amplified KADCYLA® Breast carcinoma IHC 3+ or ISH amplified a ENHERTU® b Breast carcinoma IHC 0 with membrane staining, IHC 1+ or IHC 2+/ISH non-amplified ENHERTU® Biliary tract cancer c IHC 3+ ZIIHERA® Gastroesophageal adenocarcinoma c IHC 3+ or IHC 2+/ISH amplified ZIIHERA® in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr d Gastroesophageal adenocarcinoma c IHC 3+ ZIIHERA® in combination with fluoropyrimidine- and platinum-containing chemotherapy d a See Scoring Convention section for use of ISH in context of the indication for use. b See ENHERTU® product label for specific clinical circumstances guiding HER2 testing. c Biliary tract cancer and gastroesophageal adenocarcinoma indications are only approved for use with BenchMark ULTRA instrument. d See the ZIIHERA® product label for specific clinical circumstances guiding HER2 testing.
Test results should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.
This product is intended for in vitro diagnostic (IVD) use.
| Indication for use | HER2 Score | Therapy |
|---|---|---|
| Breast carcinoma | IHC 3+ or IHC 2+/ISH amplified | Herceptin® |
| Breast carcinoma | IHC 3+ or IHC 2+/ISH amplified | KADCYLA® |
| Breast carcinoma | a IHC 3+ or ISH amplified | b ENHERTU® |
| Breast carcinoma | ENHERTU® | |
| c Biliary tract cancer | IHC 3+ | ZIIHERA® |
| Gastroesophageal c adenocarcinoma | IHC 3+ or IHC 2+/ISH amplified | |
| Gastroesophageal c adenocarcinoma | IHC 3+ |
Tables marked from the FDA document were reconstructed automatically. Check the original FDA document (links at the end of this page) for authoritative values.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。